MCM
AGN

Matarin Capital Management’s Allergan Inc AGN Stock Holding History

Matarin Capital Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,160
Closed -$516K – 195
2014
Q1 		$516K Buy
+4,160
New +$507K 0.3% 114

Other funds holding AGN

PSCM
Pershing Square Capital Management New York $13.7B AUM 13.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Matarin Capital Management's AGN Position: Q2 2014 in Review

Matarin Capital Management sold out of Allergan Inc (AGN) in Q2 2014, closing a stake of 4,160 shares — an estimated $516K sold.

Matarin Capital Management first reported a position in AGN in Q1 2014 and held it in 1 quarter. The position peaked at $516K in Q1 2014. 770 funds tracked by Wall St. Rank hold AGN as of Q2 2014.

  • Matarin Capital Management reported no remaining Allergan Inc position as of Q2 2014 after selling out during the quarter.
  • Matarin Capital Management sold 4,160 Allergan Inc shares in Q2 2014, an estimated $516K.
  • Matarin Capital Management first reported a position in Allergan Inc in Q1 2014 and held it in 1 quarter.
  • Matarin Capital Management's Allergan Inc position peaked at $516K in Q1 2014.
  • 770 funds tracked by Wall St. Rank held Allergan Inc as of Q2 2014.

Based on Matarin Capital Management's 13F filing for Q2 2014, filed 13 Aug 2014.